Abbreviations: AT 1 R, angiotensin II type 1 receptor; DSA, donor-specific antibody;ELISA, enzyme-linked immunosorbent assay; ET A R, endothelin type A receptor; FSGS, focal segmental glomerulosclerosis; GPCR, G protein-coupled receptor; HLA, human leucocyte antigen.
AbstractOrgan transplantation is an effective way to treat end-stage organ disease. Extending the graft survival is one of the major goals in the modern era of organ transplantation. However, long-term graft survival has not significantly improved in recent years despite the improvement of patient management and advancement of immunosuppression regimen. Antibody-mediated rejection is a major obstacle for long-term graft survival. Donor human leucocyte antigen (HLA)-specific antibodies were initially identified as a major cause for antibody-mediated rejection. Recently, with the development of solid-phase-based assay reagents, the contribution of non-HLA antibodies in organ transplantation starts to be appreciated. Here, we review the role of most studied non-HLA antibodies, including angiotensin II type 1 receptor (AT 1 R), K-α-tubulin and vimentin antibodies, in the solid organ transplant, and discuss the possible mechanism by which these antibodies are stimulated.
K E Y W O R D SAT 1 R, collagen V, HLA, K-α1-tubulin, non-HLA antibody, transplant, vimentin How to cite this article: Zhang X, Reinsmoen NL. Impact and production of Non-HLA-specific antibodies in solid organ transplantation. Int J Immunogenet. 2020;47:235-242.